QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), has presented a poster on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer’s Disease (ICAD 2010).
Posiphen® is in clinical development as an oral treatment for Alzheimer’s disease (AD). It is a small orally active compound that in rodents shows high blood brain barrier permeability. In cell cultures, normal, transgenic and trisomic mice Posiphen lowers amyloid-β precursor protein (APP) levels by inhibiting the rate of APP messenger RNA synthesis.
APP is cleaved into a number of toxic peptides, one of them being amyloid-β42 (Aβ42), the others being cleaved from the N- and C- terminal ends. These peptides attack multiple pathways of neuronal cell life leading to synaptic loss and nerve cell death. This induces dysfunction, neuroinflammation, and leads to cognitive impairment and neurodegeneration.
Back to the e-newsletter
